Ramla Fatime Tanko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ramla Fatime Tanko has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Jo Ann S Passmore
Department of Pathology, University of Cape Town, Anzio Road, Observatory, Cape Town 7925, South Africa
4 shared publications Tanya Pidwell
Department of Pathology, University of Cape Town, South Africa
3 shared publications- Katherine Gill
Desmond Tutu Health Foundation, 3 Woodlands Road, Woodstock, Cape Town 7915, South Africa
2 shared publications - Linda-Gail Bekker
Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa
2 shared publications - Lindi Masson
Life Sciences Discipline, Women’s, Children’s and Adolescents’ Health and Disease Elimination Programs, Burnet Institute
2 shared publications Adam Burgener
Center for Global Health and Diseases, Case Western Reserve University , Cleveland , USA
1 shared publication
Latest Publications
- Open Access
Distinct Cervicovaginal Cytokine Signatures Associated with Reproductive Tract Infections and Vaginal Dysbiosis Across Diverse Settings
Background: Reproductive tract infections (RTIs) and bacterial vaginosis (BV) are major causes of genital inflammation and reproductive morbidity, yet often remain undetected under syndromic management. We evaluated cervicovaginal cytokine signatures associated with RTIs and vaginal dysbiosis in women from South Africa, Madagascar, and Zimbabwe. Methods: Vaginal swabs from 676 non-pregnant, sexually-active women (18–35 years) were tested for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) , Trichomonas vaginalis (TV) , Mycoplasma genitalium (MG) , Candida spp., and BV by PCR and Nugent scoring. Cervicovaginal IL-1α, IL-1β, and IP-10 concentrations were measured by ELISA, and associations with RTIs and vaginal dysbiosis were assessed using multivariable regression and population attribution fraction analyses. Results: BV (Nugent 7–10) was the most prevalent (50.4%) and dominant contributor to elevated IL-1α and IL-1β, accounting for >60% of women with high cytokine levels. Intermediate vaginal microbiota (Nugent 4–6) showed similar inflammatory profiles and, with BV, was associated with reduced IP-10. NG was independently associated with elevated IL-1α and IL-1β, CT with elevated IL-1β and IP-10, TV with elevated IP-10, Candida spp. with elevations in all cytokines, while MG showed no independent associations. Most RTIs and vaginal dysbiosis were asymptomatic, with similar inflammatory profiles regardless of symptoms. Despite variation in baseline cytokine concentrations, infection-associated inflammatory signatures were consistent across countries. Conclusions: RTIs and vaginal dysbiosis elicited consistent inflammatory signatures across countries, with BV and intermediate microbiota driving much of the inflammatory burden. Their frequent occurrence in asymptomatic women highlights the potential of host-response biomarkers to identify otherwise undetected genital inflammation. Lay summary: Reproductive tract infections and bacterial vaginosis (BV; a common condition in which the normal protective bacteria in the vagina are replaced by a mix of other bacteria) are major causes of poor reproductive health, but many women have no symptoms and remain undiagnosed. In this study, we measured inflammatory proteins in vaginal samples from 676 women in South Africa, Madagascar, and Zimbabwe and examined how these markers were associated with infections and changes in the vaginal microbiota. We found that BV was the strongest driver of genital inflammation and that women with intermediate vaginal microbiota, often considered a transitional microbial state, showed similar inflammatory profiles. Different infections were associated with distinct inflammatory patterns, but many women with substantial inflammation had no symptoms. Importantly, these inflammatory responses were broadly similar across all three countries. Together, these findings highlight important limitations of symptom-based diagnosis and support the development of host-response diagnostics that can identify by reproductive tract infections and vaginal dysbiosis, including in women who would otherwise remain undiagnosed.
Open AccessDistinct Cervicovaginal Cytokine Signatures Associated with Reproductive Tract Infections and Vaginal Dysbiosis Across Diverse Settings
Background: Reproductive tract infections (RTIs) and bacterial vaginosis (BV) are major causes of genital inflammation and reproductive morbidity, yet often remain undetected under syndromic management. We evaluated cervicovaginal cytokine signatures associated with RTIs and vaginal dysbiosis in women from South Africa, Madagascar, and Zimbabwe. Methods: Vaginal swabs from 676 non-pregnant, sexually-active women (18–35 years) were tested for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) , Trichomonas vaginalis (TV) , Mycoplasma genitalium (MG) , Candida spp., and BV by PCR and Nugent scoring. Cervicovaginal IL-1α, IL-1β, and IP-10 concentrations were measured by ELISA, and associations with RTIs and vaginal dysbiosis were assessed using multivariable regression and population attribution fraction analyses. Results: BV (Nugent 7–10) was the most prevalent (50.4%) and dominant contributor to elevated IL-1α and IL-1β, accounting for >60% of women with high cytokine levels. Intermediate vaginal microbiota (Nugent 4–6) showed similar inflammatory profiles and, with BV, was associated with reduced IP-10. NG was independently associated with elevated IL-1α and IL-1β, CT with elevated IL-1β and IP-10, TV with elevated IP-10, Candida spp. with elevations in all cytokines, while MG showed no independent associations. Most RTIs and vaginal dysbiosis were asymptomatic, with similar inflammatory profiles regardless of symptoms. Despite variation in baseline cytokine concentrations, infection-associated inflammatory signatures were consistent across countries. Conclusions: RTIs and vaginal dysbiosis elicited consistent inflammatory signatures across countries, with BV and intermediate microbiota driving much of the inflammatory burden. Their frequent occurrence in asymptomatic women highlights the potential of host-response biomarkers to identify otherwise undetected genital inflammation. Lay summary: Reproductive tract infections and bacterial vaginosis (BV; a common condition in which the normal protective bacteria in the vagina are replaced by a mix of other bacteria) are major causes of poor reproductive health, but many women have no symptoms and remain undiagnosed. In this study, we measured inflammatory proteins in vaginal samples from 676 women in South Africa, Madagascar, and Zimbabwe and examined how these markers were associated with infections and changes in the vaginal microbiota. We found that BV was the strongest driver of genital inflammation and that women with intermediate vaginal microbiota, often considered a transitional microbial state, showed similar inflammatory profiles. Different infections were associated with distinct inflammatory patterns, but many women with substantial inflammation had no symptoms. Importantly, these inflammatory responses were broadly similar across all three countries. Together, these findings highlight important limitations of symptom-based diagnosis and support the development of host-response diagnostics that can identify by reproductive tract infections and vaginal dysbiosis, including in women who would otherwise remain undiagnosed.
- Open Access
Short-term HPV detection dynamics across hormonal contraceptive methods in adolescent girls and young women: a secondary analysis of a randomized trial in South Africa
Objectives Human papillomavirus (HPV) is the leading cause of cervical cancer, with adolescent girls and young women (AGYW) in sub-Saharan Africa carrying a disproportionately high burden of infection. Hormonal contraceptives may influence HPV acquisition, persistence, and clearance, but evidence remains inconclusive. This sub-study aimed to evaluate the impact of different hormonal contraceptives on HPV prevalence and genotype distribution in AGYW. Methods Ninety-eight HIV-seronegative AGYW aged 15–19 years from South Africa were randomized to receive one of three hormonal contraceptive methods: norethisterone enanthate (Net-EN) injectable, combined oral contraceptive pills (COCPs), or the etonorgesterol/ethinyl estradiol combined contraceptive vaginal ring (CCVR). Cervical DNA samples were collected at baseline and after 16 weeks for HPV genotyping using the HPV Direct Flow Chip test. HPV prevalence, persistence, clearance, and acquisition were analyzed across contraceptive methods. Results At baseline, HPV prevalence was high (94.9%), with no differences among contraceptive arms. After 16 weeks, HPV prevalence remained high (89.5%) across groups. No significant differences were observed in overall HPV prevalence or genotype distribution by contraceptive method. Longitudinal analysis revealed that AGYW using Net-EN tended to have a higher cumulative number of high-risk HPV (HR-HPV) genotypes that cleared whereas those using CCVR acquired more HR-HPV types and had greater HR-HPV persistence compared to other groups. Conclusions This study highlights the high burden of HPV among South African AGYW. However, different hormonal contraceptive methods did not significantly influence HR-HPV dynamics.
Open AccessShort-term HPV detection dynamics across hormonal contraceptive methods in adolescent girls and young women: a secondary analysis of a randomized trial in South Africa
Objectives Human papillomavirus (HPV) is the leading cause of cervical cancer, with adolescent girls and young women (AGYW) in sub-Saharan Africa carrying a disproportionately high burden of infection. Hormonal contraceptives may influence HPV acquisition, persistence, and clearance, but evidence remains inconclusive. This sub-study aimed to evaluate the impact of different hormonal contraceptives on HPV prevalence and genotype distribution in AGYW. Methods Ninety-eight HIV-seronegative AGYW aged 15–19 years from South Africa were randomized to receive one of three hormonal contraceptive methods: norethisterone enanthate (Net-EN) injectable, combined oral contraceptive pills (COCPs), or the etonorgesterol/ethinyl estradiol combined contraceptive vaginal ring (CCVR). Cervical DNA samples were collected at baseline and after 16 weeks for HPV genotyping using the HPV Direct Flow Chip test. HPV prevalence, persistence, clearance, and acquisition were analyzed across contraceptive methods. Results At baseline, HPV prevalence was high (94.9%), with no differences among contraceptive arms. After 16 weeks, HPV prevalence remained high (89.5%) across groups. No significant differences were observed in overall HPV prevalence or genotype distribution by contraceptive method. Longitudinal analysis revealed that AGYW using Net-EN tended to have a higher cumulative number of high-risk HPV (HR-HPV) genotypes that cleared whereas those using CCVR acquired more HR-HPV types and had greater HR-HPV persistence compared to other groups. Conclusions This study highlights the high burden of HPV among South African AGYW. However, different hormonal contraceptive methods did not significantly influence HR-HPV dynamics.
- Open Access
- 17 December 2023
- Published by BMJ in BMJ Global Health
- Vol. 8 (Suppl 10) , A63.1-A63
PA-309 Comparing the accuracy of inflammation detection using the lateral flow point of care Genital InFlammation Test (GIFT) interpreted by visual inspection versus automated reader
Background Sexually transmitted infections (STIs) and bacterial vaginosis (BV) are highly prevalent risk factors for HIV infection, partly driven by genital inflammation. We have developed a novel true point-of-care inflammation lateral flow assay called the Genital InFlammation Test (GIFT). GIFT detects the presence of elevated genital inflammatory cytokines to screen for asymptomatic STIs/BV cases that are missed in settings where syndromic management is practiced. Novel point-of-care tests (like GIFT) must benchmark their performance against the guidelines specified by the WHO’s REASSURED criteria, which includes being equipment-free. This study compared the performance of human eye reading of the GIFT device to an automated device reader. Methods Bio-banked lateral vaginal wall swabs collected from 10 women were tested for the presence of inflammation biomarker bands (IL-1alpha, IL-1beta) on GIFT devices, which were visually assessed by two independent researchers for band intensity (using G-scores between 0–10). Visual inspection of G-score band intensity was benchmarked against cytokine concentrations measured by commercial ELISA. G-score visual assessments were compared with band intensity measurements using an automated device reader (AXXIN-AX-2X-S™). Results Significant concordance was observed between visual (G-scores) for IL-1alpha and IL-1beta and automated reader intensities (rho=0.96, pConclusion This laboratory evaluation of the GIFT device performance, assessed visually or using an automated reader suggests that the reader may offer a sensitivity benefit over visual reading at lower vaginal cytokine concentrations, while accuracy will be comparable at higher concentrations.
- 17 December 2023
- Published by BMJ in BMJ Global Health
- Vol. 8 (Suppl 10) , A63.1-A63
Open AccessPA-309 Comparing the accuracy of inflammation detection using the lateral flow point of care Genital InFlammation Test (GIFT) interpreted by visual inspection versus automated reader
Background Sexually transmitted infections (STIs) and bacterial vaginosis (BV) are highly prevalent risk factors for HIV infection, partly driven by genital inflammation. We have developed a novel true point-of-care inflammation lateral flow assay called the Genital InFlammation Test (GIFT). GIFT detects the presence of elevated genital inflammatory cytokines to screen for asymptomatic STIs/BV cases that are missed in settings where syndromic management is practiced. Novel point-of-care tests (like GIFT) must benchmark their performance against the guidelines specified by the WHO’s REASSURED criteria, which includes being equipment-free. This study compared the performance of human eye reading of the GIFT device to an automated device reader. Methods Bio-banked lateral vaginal wall swabs collected from 10 women were tested for the presence of inflammation biomarker bands (IL-1alpha, IL-1beta) on GIFT devices, which were visually assessed by two independent researchers for band intensity (using G-scores between 0–10). Visual inspection of G-score band intensity was benchmarked against cytokine concentrations measured by commercial ELISA. G-score visual assessments were compared with band intensity measurements using an automated device reader (AXXIN-AX-2X-S™). Results Significant concordance was observed between visual (G-scores) for IL-1alpha and IL-1beta and automated reader intensities (rho=0.96, pConclusion This laboratory evaluation of the GIFT device performance, assessed visually or using an automated reader suggests that the reader may offer a sensitivity benefit over visual reading at lower vaginal cytokine concentrations, while accuracy will be comparable at higher concentrations.
- Open Access
- 9 March 2022
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 226 (5) , 907-919
The Effect of Contraception on Genital Cytokines in Women Randomized to Copper Intrauterine Device, Depot Medroxyprogesterone Acetate, or Levonorgestrel Implant
Background: The ECHO trial randomized women to intramuscular depot medroxyprogesterone acetate (DMPA-IM), levonorgestrel implant (LNG-implant), or copper intrauterine device (Cu-IUD). In a substudy of the ECHO trial, we tested the hypothesis that contraceptives influence genital inflammation by comparing cervicovaginal cytokine changes following contraception initiation. In addition, we compared cytokine profiles in women who acquired HIV (cases) versus those remaining HIV negative (controls). Methods: Women (n = 251) from South Africa and Kenya were included. Twenty-seven cervicovaginal cytokines were measured by Luminex at baseline, and 1 and 6 months after contraceptive iTanko et alnitiation. In addition, cytokines were measured preseroconversion in HIV cases (n = 25) and controls (n = 100). Results: At 6 months after contraceptive initiation, women using Cu-IUD had increased concentrations of 25/27 cytokines compared to their respective baseline concentrations. In contrast, women initiating DMPA-IM and LNG-implant did not experience changes in cervicovaginal cytokines. Preseroconversion concentrations of IL-1β, IL-6, and TNF-α, previously associated with HIV risk, correlated with increased HIV risk in a logistic regression analysis, although not significantly after correcting for multiple comparisons. Adjusting for contraceptive arm did not alter these results. Conclusions: Although Cu-IUD use broadly increased cervicovaginal cytokine concentrations at 6 months postinsertion, these inflammatory changes were found not to be a significant driver of HIV risk. Clinical Trials Registration: NCT02550067.
- 9 March 2022
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 226 (5) , 907-919
Open AccessThe Effect of Contraception on Genital Cytokines in Women Randomized to Copper Intrauterine Device, Depot Medroxyprogesterone Acetate, or Levonorgestrel Implant
Background: The ECHO trial randomized women to intramuscular depot medroxyprogesterone acetate (DMPA-IM), levonorgestrel implant (LNG-implant), or copper intrauterine device (Cu-IUD). In a substudy of the ECHO trial, we tested the hypothesis that contraceptives influence genital inflammation by comparing cervicovaginal cytokine changes following contraception initiation. In addition, we compared cytokine profiles in women who acquired HIV (cases) versus those remaining HIV negative (controls). Methods: Women (n = 251) from South Africa and Kenya were included. Twenty-seven cervicovaginal cytokines were measured by Luminex at baseline, and 1 and 6 months after contraceptive iTanko et alnitiation. In addition, cytokines were measured preseroconversion in HIV cases (n = 25) and controls (n = 100). Results: At 6 months after contraceptive initiation, women using Cu-IUD had increased concentrations of 25/27 cytokines compared to their respective baseline concentrations. In contrast, women initiating DMPA-IM and LNG-implant did not experience changes in cervicovaginal cytokines. Preseroconversion concentrations of IL-1β, IL-6, and TNF-α, previously associated with HIV risk, correlated with increased HIV risk in a logistic regression analysis, although not significantly after correcting for multiple comparisons. Adjusting for contraceptive arm did not alter these results. Conclusions: Although Cu-IUD use broadly increased cervicovaginal cytokine concentrations at 6 months postinsertion, these inflammatory changes were found not to be a significant driver of HIV risk. Clinical Trials Registration: NCT02550067.